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Abstract
Background: Ribosomal deficits are documented in mild cognitive impairment (MCI), which often represents an early stage
Alzheimer’s disease (AD), as well as in advanced AD. The nucleolar rRNA genes (rDNA), transcription of which is critical for
ribosomal biogenesis, are regulated by epigenetic silencing including promoter CpG methylation.
Methodology/Principal Findings: To assess whether CpG methylation of the rDNA promoter was dysregulated across the
AD spectrum, we analyzed brain samples from 10 MCI-, 23 AD-, and, 24 age-matched control individuals using bisulfite
mapping. The rDNA promoter became hypermethylated in cerebro-cortical samples from MCI and AD groups. In parietal
cortex, the rDNA promoter was hypermethylated more in MCI than in advanced AD. The cytosine methylation of total
genomic DNA was similar in AD, MCI, and control samples. Consistent with a notion that hypermethylation-mediated
silencing of the nucleolar chromatin stabilizes rDNA loci, preventing their senescence-associated loss, genomic rDNA
content was elevated in cerebrocortical samples from MCI and AD groups.
Conclusions/Significance: In conclusion, rDNA hypermethylation could be a new epigenetic marker of AD. Moreover,
silencing of nucleolar chromatin may occur during early stages of AD pathology and play a role in AD-related ribosomal
deficits and, ultimately, dementia.
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Introduction
Regulation of gene expression is achieved through genetic and
epigenetic mechanisms. While the former are strictly determined
by the DNA sequence, the latter are not [1]. Instead, they involve
chemical modifications of DNA and/or histones. Cytosine
methylation at DNA CpG sites is the principal epigenetic
modification of DNA that silences gene expression [2]. Although
epigenetic regulation may be a part of genetically-determined
programs such as X chromosome inactivation, it may also mediate
the effects of environmental factors [1,2]. For instance, in newborn
rats, maternal care determines their adult stress sensitivity by
reducing methylation of the glucocorticoid receptor gene promot-
er in the brain [3]. Hence, epigenetic dysregulation is an attractive
candidate mechanism, by which extrinsic factors interact with
genes to modulate normal or pathologic gene expression.
Epigenetic modulation has been proposed in the sporadic late-
onset Alzheimer’s disease (AD) [4]. However, of 62 loci whose
methylation pattern was compared in AD- and control cerebral
cortical samples, there were only two, S100A2 and SORBS3, which
showed changes in AD [5,6]. While links between these two genes
and AD pathology are unclear, none of the loci that are directly
involved in AD pathogenesis appeared differentially methylated
[5,6]. Instead, AD was associated with increased methylation
variability at 12 such loci [6]. However, the contribution of such
an epigenetic ‘‘drift’’ to AD pathogenesis has not been yet tested.
The expression of repeated nucleolar rRNA genes (rDNA)
initiates ribosomal biogenesis and is a subject of complex
regulation including transcriptional silencing via dynamic meth-
ylation of 26 CpG sites in the rDNA promoter [7,8]. The
nucleolar repressive complex (NoRC) increases methylation of
these sites inducing formation of silent chromatin, reducing rDNA
transcription and down-regulating ribosomal biogenesis [7,9].
Conversely, NoRC-mediated silencing promotes stability of
rDNA, presumably by suppressing recombination [10].
The ribosome is the nexus for all cellular protein translation and
reduced ribosomal activity has been suggested to be a major
contributor to the pathology of Alzheimer’s disease (AD)
[11,12,13,14]. Ribosomal depletion and accumulation of oxidized
rRNA have been observed in the AD cerebral cortex [11,12,13].
In addition, stereological studies of hippocampal neurons revealed
AD-associated reduction in nucleolar volume [15]. Conversely, in
subjects with moderate AD pathology without cognitive impair-
ment, nucleolar hypertrophy has been observed in both cortical
and hippocampal neurons [15,16]. Finally, in rat and mouse
neurons, blocking nucleolar transcription induces neurodegener-
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ation including neuronal death [17,18,19]. These results suggest
that perturbed ribosomal biogenesis contributes to the AD
pathogenesis. Therefore, the current study has been initiated to
determine whether dysregulation of rDNA methylation occurs in
AD.
Results
AD-associated increase in methyl-cytosine content in the
rDNA promoter
To determine the correlations between AD pathology and
methyl-cytosine (mC) content in the rDNA promoter, genomic
DNA was prepared from post mortem cerebrocortical samples of
23 AD patients, 10 MCI patients and 24 age-matched control
individuals (Table 1). The mC analysis consisted of bisulfite-
mediated non-methyl-cytosine conversion (C to T) followed by
PCR amplification of the rDNA promoter fragment (Fig. 1A–B).
After cloning of the PCR product, rDNA promoter sequence was
analyzed in individual clones. Because rDNA is composed of the
repeated 45S rRNA genes, at least 20 unique clones were analyzed
for each subject. The heat maps in Fig. 1C–D illustrate average
mCpG fractions for each rDNA CpG site in each of the analyzed
subjects. Importantly, sequence analysis of the unconverted
genomic DNA from all AD- and control subjects revealed no
CpG polymorphisms in the rDNA promoter (data not shown).
Although potential polymorphisms removing CpGs were detected
in individual rDNA clones, their relative rarity and limited extent
(of 1400 analyzed clones, 3 showed loss of one or two CpG sites/
clone) further support the notion that bisulfite mapping analysis
was not confounded by variations in DNA sequence. Finally, at
least for the CpG site #23 (position 29 relative to transcription
start site) we validated observations obtained with bisulfite
mapping using the methylation-sensitive restriction endonuclease
HpaII (Figure S1).
As in the human rDNA promoter average density of CpG
methylation across all individual CpG sites appears critical for
silencing nucleolar chromatin [7], we initially compared that
parameter between the studied groups (Fig. 2). In the parietal
cortex samples from control individuals, the mean mCpG density
6 SEM in the rDNA promoter was 25.3563.55% (Fig. 2A). In the
MCI-affected prefrontal cortex, that number was 50.6765.33%
(control vs. MCI, p = 0.0002, Fig. 2A). Although the mCpG
content decreased in the AD parietal cortex to 36.7963.21% (AD
vs. MCI, p = 0.025, Fig. 2A), the hypermethylation trend was still
present in that region (AD vs. control, p = 0.061, Fig. 2A). In the
prefrontal cortex, mCpG content in the rDNA promoter increased
from 22.262.08% in controls to 3463.02% in AD (p= 0.003,
Fig. 2B). The AD-associated changes of the mCpG density in the
rDNA promoter were accompanied by altered distribution of
differentially methylated rDNA promoter units. In average control
parietal cortex, 77% and 9.5% of all analyzed clones contained
#40 and .60% mCpGs, respectively (Fig. 2C, p,0.001). In
addition, 54% clones contained 20% or less mCpGs (Fig. 2C).
Similar distribution pattern was also observed in the control
prefrontal region indicating that in human cerebral cortex most
rDNA units remain relatively unmethylated. In contrast, that
pattern was reversed in the MCI parietal cortex (34.5 and 48%
clones with #40 and .60% mCpGs, respectively, Fig. 2C) or
flattened in the AD parietal and the prefrontal cortices (Fig. 2C–
D). Such flattening appeared greater in the prefrontal than the
parietal cortex (Fig. 2C–D).
In the AD cerebellum, which lacks advanced AD-type
pathology, mCpG frequency in the rDNA promoter was similar
in AD and control groups (20.862.8% vs. 2865.7%, respectively,
ANOVA p.0.05, Fig. S2). In addition, analysis of total mC
content in the genomic DNA from the parietal- and the prefrontal
cortex or the cerebellum revealed no differences between AD,
MCI, and control individuals (Fig. S3). Hence, in tissue with AD-
induced neurodegeneration, the rDNA promoter but not the
whole genome becomes hypermethylated. In addition, the greatest
rDNA hypermethylation is associated with relatively early stages of
AD pathology.
Distribution of the AD-hypermethylated CpGs in the
rDNA promoter
Comparison of 26 individual CpGs that are located in the
rDNA promoter revealed that 21 of them are significantly
hypermethylated in MCI parietal cortex (SAM p,0.05, Fig. 3A).
In the upstream control element (UCE; positions 2186 to 251
relative to the transcription start site) 15 of 18 CpGs were
hypermethylated. In the core promoter (CP; positions 249 to 20),
increased methylation was observed in 6 of 8 CpGs. In AD
parietal cortex, the number of hypermethylated CpGs was
reduced to 12 (7 in the UCE and 5 in the CP, SAM p,0.05,
Fig. 3B). In AD prefrontal cortex, there were 7 and 8
hypermethylated CpGs in the UCE and the CP, respectively
(SAM p,0.05, Fig. 3C). In addition, in all groups many
‘‘unaffected’’ CpGs showed MCI- and/or AD-associated hyper-
methylation trends resulting in apparently even hypermethylation
pattern across large portions of the rDNA promoter (Fig. 3).
Indeed, local regression analysis, which took such trends into
account, revealed that hypermethylation is a significant and
uniform direction of the MCI effects on all CpGs of the rDNA
promoter (Fig. 4A). Likewise, extended hypermethylation areas of
the rDNA promoter were revealed in the cerebro-cortical samples
from the AD group (Fig. 4B–C). MCI/AD-associated hyper-
methylation of large portions of the rDNA promoter is consistent
with appearance of silenced nucleolar chromatin, which in
humans is linked to an overall increase in methylation density of
the rDNA promoter [7]. In addition, robust expression of rDNA
hypermethylation in MCI suggests that such a nucleolar silencing
appears at relatively early stages of AD pathology.
At the single CpG level, no AD hypermethylation was observed
in the cerebellar rDNA promoter (Fig. S4). While some CpGs
showed a trend towards hypomethylation, local regression analysis
did not confirm significance of such changes (Fig. S4). These
findings support specificity of the association between hyper-
methylation of the rDNA promoter and AD-related neurodegen-
eration in the cerebral cortex.
Biological significance of the AD-associated
hypermethylation of the rDNA promoter
The rDNA promoter methylation reduces Pol1-mediated
transcription of rRNA [7]. In post mortem material, high
sensitivity of Pol1 to hypoxia limits the use of direct indicators of
Pol1 activity including expression of the relatively unstable 45S
rRNA primary transcript [20]. Conversely, very high stability of
mature rRNAs makes them poor Pol1 indicators as well [18].
Consistent with that notion, the only significant change in rRNA
levels was reduction of 28S rRNA in AD prefrontal cortex
(0.3560.09 fold controls, p = 0.0083), while 18S rRNA and 5.8
rRNA were unaffected (Fig. S5).
Another consequence of rDNA promoter methylation is
increased stability of rDNA repeats presumably due to decreased
recombination rate between them [10]. Since rDNA hypomethy-
lation reduced rDNA content in a cell line and declining rDNA
levels were reported during human aging [10,21], one could
Silencing of rRNA Genes in Alzheimer’s Disease
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expect that AD-associated rDNA hypermethylation may result in
higher genomic content of rDNA as compared to age-matched
controls.
To determine rDNA content a quantitative real time-PCR
(qRT-PCR) method that was originally developed to analyze D.
melanogaster rDNA was adapted for human samples [22].
Amplification of rDNA was achieved by primers complemen-
tary to the 18S rRNA exon. For normalization, the gene for
tRNAK-CTT was selected as it represents repeated DNA (17
almost identical copies per haploid) that, in contrast to rDNA, is
not clustered together [23]. Therefore, tRNAK-CTT gene provides
insight into genomic stability across multiple chromosomes
while being less likely than rDNA to undergo recombination-
associated loss. In the MCI and AD parietal cortex, the mean
rDNA/tRNAK-CTT ratio was 1.5- and 1.69- fold higher than in
age-matched controls, respectively (MCI vs. control, p = 0.0014;
AD vs. control, p = 0.0013, Fig. 5A). Similar increase was also
observed in AD prefrontal cortex (2.17 fold controls, p = 0.0017,
Figure 1. Methyl-cytosine (mC) mapping of the rDNA promoter region. A, The rDNA gene unit. The location of the promoter region that was
selected for bisulfite mapping of methyl cytosines is indicated by a box. That analyzed region included the Upstream Control Element (UCE) and the
Core Promoter (CP) which contain 26 CpG methylation sites that are critical for epigenetic regulation of nucleolar transcription (for more detail, see
Fig. S1). B. Nucleotide sequence of the human rDNA promoter. The numbers on the right indicate positions relative to the transcription start site at
position +1 (arrow); Potentially methylated CpG dinucleotides are marked grey and numbered. C, Bisulfite sequencing analysis of parietal cortex from
control-, MCI-, and AD individuals (n = 10 for each group). D. Bisulfite sequencing analysis of prefrontal cortex from control-, AD individuals (n = 15 for
each group). In C–D, each column represents one individual. Rows represent each of the potentially methylated 26 CpG sites in the rDNA promoter in
59 to 39 orientation. The data (% methylation for a given CpG) are from analyzing 20 unique clones for each subject.
doi:10.1371/journal.pone.0022585.g001
Table 1. Demographic and psychiatric profile of AD patients
and controls.
Control MCI AD
Number of subjects 24 10 23
Age (years) 85.4661.25a 86.661.86a 83.561.24a
Sex (F:M) 16:8 7:3 12:11
Brain weight (g) 1176625.27a 1150630.48a 1096627.31a
PMI (hr)b 2.6460.15a 3.0560.36a 3.0360.10a
MMSEc 28.3760.33a 22.3361.84a 9.8261.34a
Footnotes:
aMean Standard Error of the Mean (SEM);
bPMI, Post Mortem Interval;
cMMSE, Minimental State Examination score.
doi:10.1371/journal.pone.0022585.t001
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Fig. 5B). In the cerebellum, similar values of rDNA/tRNAK-CTT
ratio were observed in AD and control groups (p.0.05, Fig. 5C).
As for all analyzed samples the velocities of rDNA- and tRNAK-
CTT PCR product accumulation over the subsequent qRT-
PCR cycles were similar irrespective of diagnosis or the rDNA
methylation, we concluded that the identified differences in
rDNA content were not artifacts of differential amplification
efficiency. Thus, in AD-related neurodegeneration, hyper-
methylation of the rDNA promoter may trigger functional
changes of nucleolar chromatin including increased rDNA
stability.
Discussion
This study demonstrated hypermethylation of the rDNA
promoter correlated with AD-type pathology in the parietal
and prefrontal cortex but not the cerebellum. The level and range
of the hypermethylation was relatively greater in MCI than in
late stage AD. There was a MCI-associated reversal of a bias
towards enrichment for hypomethylated rDNA units that was
present in controls as well as the late stage AD. In MCI the
increased methylation density appeared uniformly distributed
across the rDNA promoter. However, in later stage AD, large
portions of the rDNA promoter remained hypermethylated. In
addition, the MCI/AD-associated hypermethylation of the rDNA
promoter was accompanied by increased content of rDNA
suggesting its greater stability. Conversely, global genomic
content of mC was unrelated to AD status. Thus, in cerebral
cortex, AD-related hypermethylation of the rDNA promoter may
be associated with repressive chromatin conformation in the
nucleolus likely contributing to diminished ribosomal biogenesis
and reduced protein synthesis.
Figure 2. Effects of MCI and AD on mC content in the rDNA promoter. A–B, Average % mC in the rDNA promoter (% rDNA methylation) in
the parietal- (A), and the prefrontal cortex (B). Individual values are depicted by squares; mean values are indicated by the lines intersecting the error
bars (SEM); p values and number of analyzed cases (n) are indicated. In the AD-affected prefrontal cortex, the rDNA promoter is hypermethylated. C–
D, The distribution of differentially methylated rDNA promoter clones is affected by MCI and AD. For each sample, % rDNA clones were determined
within 5 ranges of mC content; a range definition ‘‘(20,40.’’ means more than 20 and less than-, or, equal to 40% mC. Mean values 6SEM are
presented for each group of subjects. The bias towards hypomethylated clones is present in controls (ANOVA, p,0.001). That trend is disrupted or
flattened in MCI or AD, respectively (two-way ANOVA, interaction between mC range and diagnosis, p,0.001); *, p,0.05 for post-hoc comparisons
against in-range controls.
doi:10.1371/journal.pone.0022585.g002
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The excessive silencing of rDNA is the most robust change in
the AD brain epigenome that has so far been identified. Unlike
other known epigenetic irregularities in AD, hypermethylation of
the rDNA promoter appears to be a component of an AD
associated pathological cascade. While similar rDNA mC content
has been reported in peripheral blood cells from AD- and control
Figure 3. Effects of MCI and AD on distribution of mCpGs across the rDNA promoter. Percent CpG methylation at each of 26 individual
CpG sites located in the rDNA promoter in samples from parietal- (A–B) and prefrontal cortex (C). For the purpose of clarity, parietal cortex data for
MCI and AD groups are presented on separate graphs. The controls are the same in both cases. Data are means 6 SEM for each analyzed group of
cases (n as in Fig. 1); *, p,0.05 (SAM statistics as compared to controls).
doi:10.1371/journal.pone.0022585.g003
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subjects [24], our data suggest that changes in rDNA promoter
methylation are specific to cells directly confronted with AD
pathology.
Our results demonstrate that rDNA hypermethylation is most
strongly associated with early stages of AD pathology. Such
kinetics could indicate that the primary site of rDNA hypermethy-
lation are nuclei of degenerating neurons that are lost in the later
stage AD. Conversely, it is tempting to speculate that increasing
reactive gliosis could be associated with reappearance of the active,
hypomethylated rDNA units. However, we can not exclude an
alternative possibility that MCI/AD-associated hypermethylation
of rDNA is an effect of increased frequency of non-neuronal cells
such as reactive glia if their rDNA methylation levels are higher
than those of normal resident cells of the analyzed regions.
In cerebral cortex, the effects of AD on rDNA methylation were
not accompanied by reduced levels of mature rRNAs except a
decline of 28S rRNA in prefrontal cortex. Similar decline of 28S
but not 5.8S or 18S rRNA was reported by Ding et al. in parietal
cortex from MCI- and AD subjects [12]. However, we observed
no 28S reduction in that region. As we used similar methodology
to analyze samples from the same cohort as Ding et al., this
discrepancy may reflect high individual and/or regional variability
Figure 4. Local regression analysis of mC content across the rDNA promoter. After logarithmic transformation of the data from Fig. 3, the
mean differences in methylation of each of 26 individual CpG sites in the rDNA promoter were determined as indicated. A, Local regression analysis of
the mean difference between MCI- and control groups (parietal cortex) indicates significant hypermethylation of all CpGs of the rDNA promoter. The
circles indicate the actual mean difference values; the black solid line represents a smoothed regression fit of those values across the rDNA promoter
region; the green lines indicate the border of the 95% confidence range for the actual values (dashed line) or the smoothed regression (solid line).
Note that the black smoothed regression line does not leave the 95% confidence range, indicating a significant hypermethylation trend for all the
CpG sites. B–C, Similar analysis of the data for the AD samples from the parietal (B) and the prefrontal cortex (C) identifies AD-associated
hypermethylation of large portions of the rDNA promoter.
doi:10.1371/journal.pone.0022585.g004
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of rRNA levels. The concept that reduced rRNA transcription
results primarily in qualitative decline of the existing ribosomal
pool is supported by the observations that (i), at least upon
inhibition of Pol1 activity, brain rRNA is relatively very stable
[18], and, (ii) oxidized rRNA species accumulate in AD-affected
brain structures [11,12,13]. Therefore, a decrease in nucleolar
transcription, which is an expected consequence of the AD-related
rDNA hypermethylation, may have relatively greater negative
effect on rRNA quality but not its quantity.
Data presented in this report indicate that the AD-associated
hypermethylation of the rDNA promoter is linked to increased
stability of the rDNA loci. These observations are in agreement
with a recent report that in a mouse cell line, rDNA content has
declined following knockdown of the NoRC component, the TTF-
1-interacting protein-5 (TIP5) that is critical for DNA methyl-
transferase recruitment to the rDNA promoter [10]. Conversely,
TIP5 depletion or overexpression increased or decreased rRNA
transcription/cell growth, respectively [9,10]. Hence, despite
increasing rDNA content, the net effect of the rDNA promoter
hypermethylation on ribosomal biogenesis is negative.
The notion that hypermethylation-induced chromatin silencing
stabilizes rDNA preventing its loss during aging is consistent with
the established anti-aging effects of the yeast chromatin silencer
sirtuin, which has been proposed to decelerate yeast cell aging by
blocking rDNA recombination [25]. Although initial human
studies with limited number of subjects produced conflicting
results on rDNA maintenance in aging [26,27], recent analysis of a
larger cohort documented age-associated loss of rDNA in adipose
tissue [21]. If AD-associated rDNA hypermethylation prevents
rDNA loss, why is rDNA content elevated not only in MCI but
also in advanced AD when rDNA hypermethylation is dimin-
ished? Such a discrepancy can be explained by a model in which
the reduction in rDNA methylation in late AD is associated with
increasing content of reactive glia. As dividing cells, reactive glia
are expected to have no age-related rDNA loss [27]. In contrast, in
MCI, increased rDNA content will be mostly from degenerating
neurons which would also have their rDNA hypermethylated. In
support of such scenario, rDNA hypermethylation showed strong
correlation with rDNA content in MCI (R2= 0.73, p = 0.002) but
not in control- or AD groups. Overall, data presented in the
current report suggest that rDNA loss may occur in aging human
cerebral cortex and that this process could be antagonized by
methylation of the rDNA promoter.
Given the fact that rDNA consist of hundreds of repeated rRNA
genes, the extensive hypermethylation of the rDNA promoter is
the greatest AD-related abnormality in the epigenetic landscape of
the genome that has been so far identified. As hypermethylation of
rDNA has been associated with aging, the AD effects on rDNA
methylation may represent an excessive aging response [28,29,30].
Interestingly, the other identified DNA methylation irregularities
in AD brains have been also interpreted as enhancement of
epigenetic changes that occur during physiological aging [5,6].
Currently, it is unknown what is a direct trigger for such an
exacerbated ‘‘aging’’ of the brain rDNA in AD. However, it is
tempting to speculate that it is a consequence of exposure(s) to
Figure 5. Increased genomic rDNA content in cerebro-cortical
samples from MCI- and AD individuals. Genomic rDNA was
quantified by qRT-PCR; for normalization, tRNA-K-CTT gene was selected
as its unclustered copies are scattered throughout several human
chromosomes providing a good control of the non-rDNA genome
stability. The relative rDNA content was calculated as a ratio of rDNA to
tRNA-K-CTT. A, In parietal cortex increased rDNA content was observed
both in MCI and AD. B–C, AD- associated increase in rDNA content in
the prefrontal cortex (B) but not the cerebellum (C). Individual values
are depicted by squares; mean values are indicated by the lines
intersecting the error bars (SEM); p values and numbers of analyzed
cases (n) are shown.
doi:10.1371/journal.pone.0022585.g005
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such socio-environmental factors facilitating AD development as
social stress, neurotrauma or heavy metals [4]. Alternatively,
nucleolar silencing could be a secondary response to AD-
associated b-amyloidosis, tauopathy, inflammation and/or oxida-
tive stress. Finally, it may represent an action of a novel genetic
factor that by increasing rDNA methylation and/or disrupting its
demethylation increases AD susceptibility. For instance, a DNA
demethylation enzyme TET1 is located in a chromosome 10
region that harbors a relatively strong susceptibility locus for the
late onset AD [31,32]. Our future studies will address the possible
causes of AD-associated changes in rDNA methylation.
Taken together, our results indicate that hypermethylation of
the rDNA promoter is a likely contributor to ribosomal deficiency
in AD-affected brains. By reducing nucleolar transcription and
subsequently decelerating ribosomal turnover, hypermethylation
of the rDNA promoter may participate in qualitative decline of the
rRNA component of brain ribosomes contributing to AD-
associated synapse loss and dementia. Therefore, the epigenetic
regulation of nucleolar transcription is a potential target to
intervene against AD. Finally, nucleolar silencing may contribute
to other age-related neurodegenerative diseases.
Materials and Methods
Subjects and sample preparation
The donors were participants of the IRB-approved University of
Kentucky AD Center cohort and were followed for at least 2 years
before death [33]. The follow up included annual Minimental
State Examination (MMSE) as well as neurological and physical
examinations. The donors had no history of substance abuse, head
injury, encephalitis, meningitis, epilepsy, or stroke/transient
ischemic attack. The MMSE score closest to death was used as
an indicator of overall cognitive status. During autopsy (5 or less
hours after death), tissue samples including parietal cortex
(Brodmann Areas 39 and 40), prefrontal cortex (Brodmann Area
9) and cerebellum were processed for neuropathological evalua-
tions or flash-frozen in liquid nitrogen and stored at 280uC, as
described previously [33,34]. All included AD subjects met the
clinical and histophathological criteria for diagnosis of AD [33,34].
The MCI group was categorized as defined previously according
to conventional clinical-pathological consensus criteria [33,34].
Summary of donor data is presented in Table 1.
Genotyping of the rDNA promoter region
Genomic DNA was isolated from flash frozen tissue samples
using DNeasy Blood & Tissue Kit (Qiagen). A fragment including
the rDNA promoter region was PCR-amplified and sequenced
bidirectionally (detailed primer information is in Table S1).
Bisulfite Mapping of rDNA Methylation
A previously described methodology was used with modifica-
tions [8]. Briefly, genomic DNA was isolated from frozen
samples and unmethylated cytosines were converted with
bisulfite using EZ DNA Methylation-Direct Kit (Zymo Re-
search). The converted DNA was a template for PCR
amplification of the rDNA promoter containing 26 potential
mCpGs (detailed primer information is in Table S1). The PCR
product was cloned in pGEM-T vector and at least 20 clones
from each sample were sequenced using the SP6 universal
reverse primer. Sequencing results were analyzed with software
developed in our laboratory that can be obtained upon request.
Clones with incomplete bisulfite conversion of non-CpG
cytosines were excluded from analysis. To avoid a bias due to
multiplication of identical clones, only such clones that
represented unique patterns of CpG methylation were included
in the final analysis of each sample.
Methyl-sensitive restriction enzyme analysis of
methylation
Methylated-C sensitive restriction analysis was performed as
described previously [35]. DNA (200 ng) was treated with HpaII
over night and qRT PCR was run with primers specific to rDNA
promoter fragment that contain the CpG#23 (position 29 from
the transcription start site, Fig. 1B; primer details are in Table S1).
Results were normalized for undigested (input) DNA. The qRT-
PCR data were analyzed using the standard curve method.
Methylated DNA content in the genome
Genomic DNA was isolated as for genotyping. The content of
mC was determined using 100 ng of DNA/sample and the
commercial mC ELISA system (Imprint Methylated DNA
Quantification Kit, Sigma-Aldrich). For each sample, triplicate
determinations were performed.
Analysis of genomic rDNA content
The previously described qRT-PCR technique was used to
determine rDNA content in the genomic DNA [22]. The
amplified portions of the rDNA cistron mapped within the 18S
rRNA coding region. The content of tRNAK-CTT gene DNA was
used as a normalization control. Details concerning the primers
are in Table S1. The qRT-PCR data were analyzed using the
standard curve method.
Analysis of 18S, 5.8S and 28S rRNA levels
RNA isolation, reverse-transcription with random hexamers
and quantitative real time PCR (qRT-PCR) with SYBR Green
(SuperArray Bioscience) were performed using standard method-
ology that was described before [36] except that qRT-PCR data
were analyzed using the standard curve method. Detailed primer
information is in Table S1.
Statistical analysis
Comparisons of individual rDNA methylation sites were
accomplished using a modified significance analysis of microarrays
(SAM) [37]. The detailed description of the modifications
including addition of local regression analysis is provided as a
supplementary information (Methods S1). SAM has been
successfully applied to analyze complex genome methylation
patterns such as those in rDNA [38]. Importantly, the modified
SAM model makes no functional assumptions about the
methylation data at different sites and takes proper account of
the correlation structure between sites at the same time allowing
for the control of the probability of false discoveries. The average
rDNA- and total genomic DNA mC levels as well as rDNA
content were compared by ANOVA and Fisher LSD post-hoc tests.
Supporting Information
Figure S1 Confirmation of rDNA promoter hyper-
methylation in MCI parietal cortex using the mC-
sensitive restriction endonuclease HpaII. A, Hypermethy-
lation of rDNA promoter CpG#23 (position -9 relative to
transcription start site) was confirmed by a mC-sensitive restriction
endonuclease HpaII. If CpG#23 was unmethylated, cleavage by
HpaII destroyed a template for qRT PCR. Increased levels of the
HpaII-resistant template indicated rise in mC frequency at that
site. The results for HpaII-treated genomic DNA were normalized
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against the non-treated DNA. Data are means 6 SEM from 5
MCI- and 5 control individuals. B, Hypermethylation of CpG#23
as observed in the same individuals using bisulfite sequencing (for
more details, see Figs. 1&3).
(TIF)
Figure S2 Effects of AD on mC content of the rDNA
promoter in the AD pathology-free cerebellum. A,
Average % mC in the rDNA promoter (% rDNA methylation).
Individual values are depicted by squares; mean values are
indicated by the lines intersecting the error bars (SEM); p values
and numbers of analyzed cases (n) are indicated. In the AD-
affected prefrontal cortex, the rDNA promoter is hypermethy-
lated. B, The distribution of differentially methylated rDNA
promoter clones indicates overrepresentation of hypomethylated
rDNA units in control samples (p,0.001). Similar pattern is
present in AD. For more details, see description of the Fig. 2.
(TIF)
Figure S3 Effects of MCI and AD on mC content in total
genomic DNA as determined with an mC-specific ELISA.
A, In parietal cortex, neither MCI nor AD affected mC content in
total genomic DNA (global DNA methylation). B–C, AD had also
no effects on that parameter in the prefrontal cortex (B) or the
cerebellum (C). Individual values are depicted by squares; mean
values are indicated by the lines intersecting the error bars (SEM);
p values and numbers of analyzed cases (n) are shown.
(TIF)
Figure S4 Effect of AD on distribution of CpG methyl-
ation across the rDNA promoter in the cerebellum. A,
Percent methylation at each of 26 individual CpG sites located in
the rDNA promoter region. The data represent averages 6 SEM
from 5 AD- and 5 non-AD control individuals; *, p,0.05 (SAM
statistics). B, Local regression analysis of the AD effects on rDNA
promoter methylation in the cerebellum. Mean differences
between AD- and control groups are plotted. The circles indicate
the actual mean difference values; the black solid line represents a
smoothed regression fit of those values across the rDNA promoter
region; the green lines indicate the border of the 95% confidence
range for the actual values (dashed line) or the smoothed
regression (solid line). For more details, see description of Figs. 3–
4.
(TIF)
Figure S5 Effects of MCI and AD on 18S-, 5.8S- and 28S
rRNA levels. Quantitative real time PCR analysis of rRNAs was
performed using the standard curve method. A–C, In parietal
cortex, MCI or AD did not affect 18S-, 5.8S-, or 28S rRNA levels.
D–F, In prefrontal cortex an AD- associated decrease of 28S-, but
not, 18S-, or 5.8S rRNA was observed. Individual values are
depicted by squares; mean values are indicated by the horizontal
bars that intersect the error bars (SEM); p values are shown; n = 10
or 15 for each group in A–C or D–F, respectively.
(TIF)
Table S1 Primers and PCR conditions.
(DOC)
Methods S1 A text file containing detailed description of
the modified SAM statistics.
(DOC)
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